Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Feb 2023)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy
Guo Chen, … , Paul W. Doetsch, Xingming Deng
Guo Chen, … , Paul W. Doetsch, Xingming Deng
Published December 11, 2017
Citation Information: J Clin Invest. 2018;128(1):500-516. https://doi.org/10.1172/JCI92742.
View: Text | PDF
Research Article Cell biology

Targeting Mcl-1 enhances DNA replication stress sensitivity to cancer therapy

  • Text
  • PDF
Abstract

DNA double-strand breaks (DSBs) are mainly repaired either by homologous recombination (HR) or by nonhomologous end-joining (NHEJ) pathways. Here, we showed that myeloid cell leukemia sequence 1 (Mcl-1) acts as a functional switch in selecting between HR and NHEJ pathways. Mcl-1 was cell cycle–regulated during HR, with its expression peaking in S/G2 phase. While endogenous Mcl-1 depletion reduced HR and enhanced NHEJ, Mcl-1 overexpression resulted in a net increase in HR over NHEJ. Mcl-1 directly interacted with the dimeric Ku protein complex via its Bcl-2 homology 1 and 3 (BH1 and BH3) domains, which are required for Mcl-1 to inhibit Ku-mediated NHEJ. Mcl-1 also promoted DNA resection mediated by the Mre11 complex and HR-dependent DSB repair. Using the Mcl-1 BH1 domain as a docking site, we identified a small molecule, MI-223, that directly bound to BH1 and blocked Mcl-1–stimulated HR DNA repair, leading to sensitization of cancer cells to hydroxyurea- or olaparib-induced DNA replication stress. Combined treatment with MI-223 and hydroxyurea or olaparib exhibited a strong synergy against lung cancer in vivo. This mechanism-driven combination of agents provides a highly attractive therapeutic strategy to improve lung cancer outcomes.

Authors

Guo Chen, Andrew T. Magis, Ke Xu, Dongkyoo Park, David S. Yu, Taofeek K. Owonikoko, Gabriel L. Sica, Sarah W. Satola, Suresh S. Ramalingam, Walter J. Curran, Paul W. Doetsch, Xingming Deng

×

Figure 4

Depletion of Mcl-1 downregulates HR and upregulates NHEJ.

Options: View larger image (or click on image) Download as PowerPoint
Depletion of Mcl-1 downregulates HR and upregulates NHEJ.
(A) Schematic ...
(A) Schematic diagram of HR and NHEJ reporter systems. HR reporter is composed of 2 defective GFP genes that can be rescued only by HR, resulting in GFP fluorescence. In the NHEJ reporter, GFP is interrupted by an adenoviral exon (Ad2) and can be restored upon HindIII digestion and NHEJ repair. (B) HR activity was compared in WT and Mcl1–/– MEFs. Data represent the mean ± SD, n = 3 per group. **P < 0.01, by 2-tailed t test. (C) Mcl-1 was knocked down using Mcl-1 siRNA from U2OS DR-GFP cells, followed by analysis of HR activity. Data represent the mean ± SD, n = 3 per group. **P < 0.01, by 2-tailed t test. (D) NHEJ activity was compared in WT and Mcl1–/– MEFs. Data represent the mean ± SD, n = 3 per group. *P < 0.05, by 2-tailed t test.

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts